Insider Selling: Knight Therapeutics Inc. (TSE:GUD) Senior Officer Sells C$116,022.00 in Stock

Knight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri sold 20,000 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of C$5.80, for a total transaction of C$116,022.00.

Knight Therapeutics Trading Down 0.7 %

TSE GUD opened at C$5.70 on Friday. The company’s 50-day moving average price is C$5.87 and its 200-day moving average price is C$5.56. The company has a current ratio of 3.34, a quick ratio of 1.79 and a debt-to-equity ratio of 9.20. The stock has a market cap of C$577.87 million, a PE ratio of -35.63, a PEG ratio of -1,013.50 and a beta of 0.46. Knight Therapeutics Inc. has a 12 month low of C$4.35 and a 12 month high of C$6.22.

Knight Therapeutics (TSE:GUD) last issued its earnings results on Thursday, May 9th. The company reported C($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C($0.06). Knight Therapeutics had a negative return on equity of 2.21% and a negative net margin of 5.25%. The business had revenue of C$86.60 million for the quarter, compared to the consensus estimate of C$80.27 million. Equities research analysts forecast that Knight Therapeutics Inc. will post 0.0303448 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GUD. Raymond James boosted their price objective on shares of Knight Therapeutics from C$7.00 to C$7.50 and gave the company an “outperform” rating in a research report on Wednesday, March 6th. Stifel Nicolaus upped their price target on shares of Knight Therapeutics from C$5.40 to C$5.75 in a report on Friday, May 10th. Finally, Royal Bank of Canada upped their price target on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the stock an “outperform” rating in a report on Friday, March 22nd.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.